PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.03), $0.39 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $150.83 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.